Dr. Yuelei Shen Shared His Insights During Investment Reports/Newsweek Interview
January 19, 2024
Source: Investment Reports This interview, together with other interviews with the industry’s leading figures, will be published in the second edition of The New Era of Life Sciences, a Newsweek’s special annual feature. The full report will showcase promising innovations, and highlight the most important challenges the industry currently faces. The report will be launched […]
Join us at PepTalk 2024: Jan 16-19
Join us at booth #717 at PepTalk 2024 from January 16-19 in San Diego, CA! Dr. Frank An, Senior Director, Antibody Therapeutics will be presenting “Improving Anti-Tumor Activity with Bispecific Antibody Drug Conjugates” at 2:20 pm PST on Jan 19. Whether you need humanized models, PK/PD services, or antibody discovery services, we’d love to partner […]
Biocytogen’s YH008 Greater China Licensee Chipscreen NewWay Announces First-Patient-In for Bispecific Antibody NWY001, a Next-Gen Tumor Immunotherapy
Beijing, China, January 5, 2024 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) partner Chipscreen NewWay Biosciences (“Chipscreen NewWay”) achieved first-patient-in for a phase I clinical trial evaluating a PD-1 x CD40 bispecific antibody, NWY001 (originally YH008), at Sun Yat-Sen University Cancer Center in China, the trial-leading institution. The trial is a multi-center, non-randomized, […]
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma
BEIJING, China and BOSTON, Massachusetts, USA—Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces that it has entered into an Exclusive Option and License Agreement with Radiance Biopharma Inc. (“Radiance”), a biotechnology company specializing in developing next generation Antibody Drug Conjugates. The […]
Manhattan BioSolutions Enters into Evaluation and Potential Licensing Agreement with Biocytogen for Use of Innovative Antibodies in Targeted Therapies
New York City, New York and Beijing, China, January 3, 2023 – Manhattan BioSolutions, Inc. (Manhattan Bio or MABS), an emerging biotech company developing innovative precision biologics, today announced it has entered into an evaluation and potential licensing agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focused on the […]
Biocytogen BDL and Leadership Team to Participate in the 42nd Annual JPM Healthcare Conference and its Satellite Conferences
Biocytogen (HKEX: 02315) will attend the upcoming 42nd J.P. Morgan (JPM) Healthcare Conference and several satellite conferences, which will be held in San Francisco from January 7-12, 2024. Dr. Chaoshe Guo, Vice President and Global BD Head of Biocytogen, will be onsite with members of the Business Development & Licensing (BDL) team to discuss and […]
Biocytogen and CtM Bio Achieve Milestone Progress in Co-Developing a TCR-mimic Antibody-based Multi-Specific T Cell Engager Targeting WT1/HLA-A02
December 27, 2023
Beijing, China and Shanghai, China, December 27, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and CtM Biotech (Shanghai) Co., Ltd (“CtM Bio”) today jointly announce that the development of a tri-specific T cell engager for an intracellular target achieved milestone progress. In just one year since the start of the collaboration, the […]
Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences
December 19, 2023
Beijing, China and San Diego, US, December 19, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd (“Biocytogen”, HKEX: 02315) today announced that it has entered into an antibody evaluation and option agreement with Neurocrine Biosciences, Inc. The agreement grants Neurocrine Biosciences access to Biocytogen’s fully human antibodies against multiple specified targets, with an option to license […]
Webinar: Maximize Your Drug Design Possibilities with RenNano-derived Fully Human Nanobodies
December 19, 2023
Our webinar “Maximize Your Drug Design Possibilities with RenNano-derived Fully Human Nanobodies” was live at 11AM EST on January 24, 2024. About the webinar: Compared to traditional antibodies, nanobodies are significantly smaller in size, which is advantageous for penetrating tumors and crossing the blood-brain barrier. The protruding CDR3 regions of nanobodies make them better […]
Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors
December 18, 2023
Beijing, China and Barcelona, Spain, December 18, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery and development of novel antibody therapeutics, today announces an antibody evaluation, option and license agreement with Ona Therapeutics (“Ona”), a Spanish biotech company specialized in unravelling novel biology to design […]
